# US 2025/0081998 A1 · Development of amyloglucosidase as a medicinal food or dietary supplement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0081998 A1
- Document ID: US20250081998A1
- Status: Published application
- Kind: A1
- Application number: 18/960,342
- Filed: 2024-11-26
- Published: 2025-03-13
- Earliest claimed: 2018-04-18
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Antone Robert Opekun, JR.
- Web page: https://patentgrep.com/patent/US20250081998A1

## CPC

- A23L 29/06: {Enzymes}
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- C12N 9/242: {Fungal source}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C12Y 302/01003: Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12Y: ENZYMES

## Abstract

Embodiments of the disclosure include particular amyloglucosidase (AMG) compositions formulated as a nutriceutical or medicinal food, for example. The AMG compositions are formulated at a specific dosage and/or are lacking in one or more toxins or have substantially reduced levels of toxin, such as deoxynivalenol (vomit toxin). The AMG compositions are provided to individuals in need thereof, such as an individual with or at risk for congenital sucrase isomaltase syndrome, functional bowel disorders, small bowel bacterial overgrowth, protein-calorie malnutrition (marasmus), radiochemotherapy-induced mucositis and/or short-gut syndrome.

## Claims

### Claim 1

A method of optimizing starch or fructans digestion in an individual, comprising the step of providing to the individual an effective amount of a composition comprising amyloglucosidase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises amyloglucosidase in a dosage that is equal to or greater than 10,000 unit releases of one gram of glucose per hour (AGU).

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is provided to the individual orally.

### Claim 4 (depends on 1)

The method of claim 1, wherein the individual is in need of treatment or prevention of congenital sucrase isomaltase syndrome, functional bowel disorders, functional bowel syndrome, functional duodenal disorders, small bowel bacterial overgrowth, radiochemotherapy-induced mucositis and/or short-gut syndrome.

### Claim 5 (depends on 1)

The method of claim 1, wherein the providing step occurs daily, weekly, monthly, or yearly.

### Claim 6 (depends on 1)

The method of claim 1, wherein the individual is malnourished.

### Claim 7 (depends on 1)

The method of claim 1, wherein the individual is an infant, child, adolescent, teenager, or adult.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is formulated in a comestible or beverage.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition is a food supplement.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is in the form of a solid, liquid, or gel.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is a capsule, tablet, pill, film, lozenge, powder, or combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition comprises amyloglucosidase and a reduced level of a toxin with reference to an amyloglucosidase composition that has not been subjected to an extraction/purification step, wherein the toxin is a mycotoxin, a ochratoxins, and/or a flatoxin.

### Claim 13 (depends on 12)

The method of claim 12, wherein the amyloglucosidase composition comprises 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 92, 94, 95, 96, 97, 98, or 99% lower amount of toxin than the reference amyloglucosidase composition.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more other therapeutic agents.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more other therapeutic agents comprise an agent that facilitates digestion of biological molecules other than starch.

### Claim 16 (depends on 14)

The method of claim 14, wherein the therapeutic agent is invertase sucrase, lactase, xylose isomerase, beta-galactosidase, or a combination thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein the one or more therapeutic agents is histamine type-2 receptor antagonists, benzimidazole derivative, or a combination thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein no added buffers, amino acids, and/or carbohydrates are in the composition.
